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ABSTRACT
Brain-Derived Neurotrophic Factor (BDNF) is considered one of the most
influential neurotrophins in the brain. It has known involvement in synaptic signaling and
interaction with estrogen in the brain (E2) to perform neuroprotective functions. Although
previous studies have examined the role of BDNF under pathologic conditions, the
detailed molecular interactions that mediate BDNF action in the adult brain remain
incompletely explored. In this study, we used protein expression analyses of hippocampal
tissue to examine the effects of whole-brain BDNF knockdown (BDNF+/- KD) on the
expression of various synaptic markers and estrogen receptors in otherwise healthy male
and female rats. Relative to wildtype (WT) controls, only the BDNF +/- KD males showed
increased levels of the presynaptic marker, synaptophysin, while exhibiting a decrease in
the postsynaptic marker, PSD-95. Glutamatergic and cholinergic neuronal markers were
not significantly changed in both the male and female rats after BDNF loss. BDNF +/- KD
males also show a uniform upregulation in estrogen receptor expression, including ER-α,
ER-β, and GPER1, which remained unchanged in the females. Taken together, our
results suggest that BDNF loss leads to disruptions in synaptic signaling mechanisms in
a sex-specific manner, and these sex differences may reflect the actions of estrogen
receptors in the hippocampus. In conclusion, our study contributes to the understanding
of sex differences in BDNF signaling in the brain. This will aid in development of novel
therapeutic targets for various neuropsychiatric and neurodegenerative disorders,
including the natural process of aging, where BDNF is a known player.
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CHAPTER ONE
OVERVIEW AND SPECIFIC AIMS
Statement of the Problem
Disrupted synaptic signaling is a well-established mechanism of several disease
states. Many authors have suggested that deficits in BDNF action play a key role in many
neuropathological disorders. As such, characterizing BDNF signaling under pathologic
conditions has been the focus of recent research. However, the action of this neurotrophin
in the brain under normal conditions remains incompletely understood. BDNF function is
also modulated by biological sex. Interestingly, sexual dimorphisms in brain structure and
function are posited to reflect the differential actions of estrogen in the brain. Mounting
evidence suggests that estrogen performs trophic actions as well, and, in collaboration
with BDNF, may ameliorate the degradation of cells via defined signaling cascades.
Therefore, to contribute to the field, this study hypothesizes that synaptic signaling is
disrupted in a rodent model of BDNF loss, and that this disruption involves alterations to
estrogen receptor signaling in a sex-specific manner. To test this hypothesis, we designed
the following specific aims.

Specific Aims
Aim 1: To determine the basal relationship between BDNF expression levels and
neuronal markers of synaptic signaling in the hippocampus of the rat brain. We will
examine markers of pre- and postsynaptic nerve connectivity, synaptophysin and PSD95, as well as markers of glutamatergic and cholinergic activity, VGLUT2 and ChAT.
1

Aim 2: To determine whether sex-differences play a role in BDNF regulation of pre- and
postsynaptic nerve connectivity and neurotransmitter activity. We will further examine the
expression levels of estrogen receptors, namely, ER-α, ER-β and GPER1, in relation to
BDNF in the hippocampus.
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CHAPTER TWO
INTRODUCTION AND LITERATURE REVIEW
In the last several decades, great strides have been made towards understanding
and improving brain health. The scientific community has continually refined search
parameters in efforts to minimize and mitigate disease states, while simultaneously
directing efforts towards promoting health and well-being. New technological
advancements afford us the ability to visualize the brain better than ever.
Electroencephalography (EEG) allows us to monitor neural networks with incredible
temporal resolution, while neuroimaging, such as functional magnetic resonance imaging
(fMRI), helps us spatially define those networks. In the medical field, better technology
has evoked a shift in how we approach diagnosis and treatment. Since we can interrogate
disease states with much greater precision, a greater emphasis has been placed on
identifying biological signs of health and disease. In biomedical sciences, researchers are
interested in identifying biomarkers associated with brain disorders so that they may
better understand the physiological conditions under which they arise. These efforts are
crucial to the development of treatments. However, our understanding of basic brain
structure and function is far from comprehensive. The basic constituents of nerve
interactions require further attention, and there remains great potential for discovery in
this domain.
It is well accepted that brain states are defined by increasingly lower-order
systems. Behavioral and cognitive states are derived from interconnected brain regions,
which are comprised of neural circuits. Those circuits can be described by neuronal
assemblies, or groups of neurons that fire together. And those assemblies can be
3

described by the information processing that occurs in the synapse between nerve cells.
Lower still, intercellular communication is determined by the intracellular goings-on of
molecules in motion—the molecular signaling cascades that alter cell excitability and
affect gene transcription. To be sure, a complete understanding of any brain state
requires an understanding of each underlying system individually, as well as and how
they interact to produce the associated phenotype. Animal research has helped reveal
the cellular and molecular mechanisms of neuronal communication, which is regarded as
the guiding principle of healthy brain function (Snyder & Smith, 2018). An on-going
objective in the field of neuroscience is to characterize mechanisms of neuronal
communication in order to better understand the role they play, both individually and
collectively, in states of health and disease.

Neurotrophins
Healthy brain function relies on neuronal mechanisms of synaptic maintenance
and regulation. These mechanisms involve the action of signaling peptides called
neurotrophins, which bind to specific transmembrane receptors to govern processes
important for neuronal health (Williams & Umemori, 2014). Four distinct members of the
neurotrophic family have been identified in the mammalian brain: nerve growth factor
(NGF) (Levi-Montalcini, 1966), brain derived neurotrophic factor (BDNF) (Barde, Edgar,
& Thoenen, 1982), neurotrophin 3 (NT-3), and neurotrophin 4/5 (NT-4/5) (Hohn, Leibrock,
Bailey, & Barde, 1990). These proteins are homologous in amino acid sequence and
structure, share genetic ancestry, and are collectively involved in neuroregulatory actions
(Huang & Reichardt, 2001). Like other proteins, neurotrophins arise from precursors
4

called proneurotrophins, which undergo proteolytic cleavage to produce mature proteins
(Seidah et al., 1996). Proneurotrophins and neurotrophins exert distinct effects on target
neurons. Their specific action reflects their differential specificity for two classes of
neurotrophin receptors: the p75 receptor (p75NTR) and the group of tyrosine receptor
kinases (Trks) (Chao, 1992). Proneurotrophins are chemically attracted to the p75NTR,
binding to its site with relatively high affinity (Greene & Kaplan, 1995). P75NTR binding has
been associated with neuronal apoptosis and other conspecific mechanisms which
oppose the actions of mature neurotrophins (B. Lu, Pang, & Woo, 2005). Mature
neurotrophins preferentially bind to their individual high-affinity protein kinase receptors
subtypes: NGF selectively binds to Trk-A; NT-3 to Trk-B and Trk-C; NT-4/5 to Trk-B; and
BDNF to Trk-B (Bothwell, 1991). The binding of neurotrophins to Trk receptors induces
intracellular signaling, which promotes neuronal growth and survival (Chao, 1992).
Neurotrophins play different roles depending on how they are released (Song,
Martinowich, & Lee, 2017). Although the traditional trophic model held that neurotrophins
are transported in a retrograde fashion, there is now evidence that some neurotrophins,
such as BDNF, are also transported in an anterograde fashion (Conner, Lauterborn, Yan,
Gall, & Varon, 1997; Fawcett et al., 1998). Generally, the anterograde release of
neurotrophins from the presynaptic cell is understood to help organize postsynaptic
densities (Vaegter et al., 2011), while the retrograde release of neurotrophins from
postsynaptic cells helps situate presynaptic vesicles. Together, these trophic actions help
support synaptic connectivity and facilitate neurotransmission, the fundamental
constituents of neuronal communication (Choo et al., 2017). The following sections will
5

focus on BDNF, exploring its putative roles in synaptic signaling, hippocampal plasticity,
and neuroprotection.
BDNF and Trk-B signaling
Since its initial purification in 1982, BDNF has been under study for its manifold
actions in the brain. Encoded by the BDNF gene (K. R. Jones & Reichardt, 1990), BDNF
protein exists in two forms. At the cellular level, proBDNF is synthesized in the
endoplasmic reticulum (Mowla et al., 2001), stored in presynaptic dense core vesicles
(Dieni et al., 2012), and then secreted by neurons in an activity-dependent manner (L.
Pozzo-Miller, 2008). In the synaptic cleft, proBDNF can undergo proteolytic processing to
produce mature BDNF (Gray & Ellis, 2008). Mature BDNF is a moderately sized (14kDa)
polypeptide comprised of 119 amino acids which forms non-covalent dimers (28kDa) and
features a basic isoelectric point (Ip≈10.1) (Barde et al., 1982). Once in the synapse,
mature BDNF action is mediated through the binding and dimerization of the Trk receptor
type B (Trk-B) located on the membrane of receptive neurons (Kelly-Spratt, Klesse, &
Parada, 2002). Following Trk-B activation, tyrosine residues found in their respective
cytoplasmic kinase domains become auto-phosphorylated. Activated tyrosine residues
allow docking of effector proteins, which in turn activate three main intracellular signaling
cascades: the phosphatidylinositol-3 kinase (PI3K), which triggers threonine/serine
kinase AKT; the extracellular signal related kinase (ERK, or mitogen-activated protein
kinase (MAPK)) pathway, which initiates several downstream effectors; and the
phospholipase-C-γ (PLC-γ) pathway, which leads to the activation of calcium-calmodulin
dependent kinase (CaMKII) (Figure 2.1) (Zheng & Wang, 2009). The PLC-γ pathway is
6

Figure 2.1. BDNF signal transduction. BDNF binds TrkB with high selectivity. TrkB dimerization promotes
subsequent autophosphorylation of c-terminal tyrosine residues that serve as docking sites for effector
molecules. Effector proteins can bind and trigger one of three signaling pathways: PLC-γ, PI3K, and ERK.
These cascades lead to phosphorylation of cAMP response element-binding protein (CREB), mediating
gene transcription important for the survival and plasticity of neurons. Activation of PLC-γ also leads to an
increase in intracellular calcium and a corresponding increase in CaMKII activity, which is thought to be
responsible for the rapid-acting effects of BDNF.
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believed to mediate the rapid ion channel effects of BDNF via the release of intracellular
calcium stores, while the sustained effects of BDNF\, which involve transcription, are
considered downstream of the MAPK and PI3K pathways (Zheng & Wang, 2009). The
three major signaling cascades downstream of BDNF-induced Trk-B activation are known
to phosphorylate cAMP response element-binding protein (CREB) (Tao, Finkbeiner,
Arnold, Shaywitz, & Greenberg, 1998). CREB-mediated gene transcription has a wellestablished role in neurogenesis, synaptic plasticity, and neuron survival (Yoshii &
Constantine-Paton, 2010).
BDNF and the hippocampus
BDNF and other neurotrophins exhibit a similar, but not identical, cellular and
regional distribution in the mammalian brain. In situ hybridization experiments have
shown that BDNF is predominantly expressed by neurons (Zafra, Hengerer, Leibrock,
Thoenen, & Lindholm, 1990), and BDNF-expressing neurons are disproportionally
concentrated in limbic structures (H. T. Zhang et al., 2007). Immunoreactivity studies
further show that BDNF and Trk-B protein expressions are particularly high in various
regions of the hippocampus (Conner et al., 1997).
The hippocampus is important for healthy cognitive function and plays a major role
in several learning and memory processes. The neuronal mechanisms underlying longterm potentiation (LTP), a cellular model for learning and memory, involve physiological
and structural changes to hippocampal neurons. Importantly, these changes reflect the
efficacy of synaptic transmission. Early studies initially demonstrated the effects of BDNF
on synaptic transmission in Xenopus cultures, where delivery of BDNF increased the
8

frequency of miniature excitatory postsynaptic currents (EPSCs) (Lohof, Ip, & Poo, 1993).
It was later confirmed that BDNF strengthens excitatory synapses and mediates longlasting enhancements to synaptic transmission in the adult hippocampus (Kang &
Schuman, 1995). Since these studies, experimental findings have more directly
supported a role of BDNF in LTP. For example, exposure of hippocampal neurons to TrkB inhibitors prevents LTP from taking place (Figurov, Pozzo-Miller, Olafsson, Wang, &
Lu, 1996), and hippocampal tissues from BDNF knockout animals exhibit impaired LTP
induction, which is rescued by reintroduction of BDNF (Patterson et al., 1996).
BDNF-induced hippocampal plasticity is also understood to protect against injury
or attenuate pathology in the injured brain. For example, Trk-B-induced activation of the
MAPK and PI3K pathways promote neuron survival and neurogenesis (Mocchetti &
Bachis, 2004), and BDNF signaling in the hippocampus has been shown to ameliorate
the effects of ischemic injury (Sheng et al., 2018). Furthermore, BDNF-induced
synaptogenesis in the hippocampus improves behavioral outcomes in several models of
disease (Xuan, Agrawal, Huang, Gupta, & Hamblin, 2015). Given these reports, there is
consensus in the field that hippocampal BDNF is neuroprotective in the injured CNS and
may

be

an

effective

therapeutic

target

for

several

neuropsychiatric

and

neurodegenerative disorders (Coughlan, Gibson, & Murphy, 2009). Investigations are
currently underway to further explore this potential.

BDNF and Neuropathology
Studies of human brain disorders have traditionally relied on the subjective
documentation of symptoms linked to impaired brain function. Symptom-based diagnostic
9

approaches carry several disadvantages, including definitional constraints of symptom
duration, the difficulty of identifying individual differences, and the inherent risk of
conflating comorbidities. Until recently, human research has involved studies in which
higher-order brain mechanisms are dysfunctional, whether due to genetics or the
environment. Now, greater emphasis has been placed on determining the fundamental
mechanisms involved in diseases of the central nervous system. There has been
increasing evidence that neuronal mechanisms of synaptic transmission and connectivity
are disrupted in neuropathologic disorders (Kouroupi et al., 2017; Samuel, Alford,
Hofstetter, & Hansen, 1997), and this has generated great interest in the idea that
dysregulated BDNF is a key player in their development.
Neuropsychiatric disorders
BDNF signaling has been implicated in neuropsychiatric disorders, including the
aggregate of affective disorders. Pharmacological studies have linked depressive
phenotypes to decreased levels of BDNF mRNA (Altar, 1999), and elevated levels of
BDNF mRNA have been associated with antidepressive-like phenotypes (Castren &
Rantamaki, 2008). Typical treatments for depression disorders are thought to act primarily
through monoaminergic synaptic transmission, and interestingly, BDNF mRNA has been
shown to increase alongside the effects of monoamine oxidase inhibitors (MOAIs) and
selective serotonin reuptake inhibitors (SSRIs) (Castren & Rantamaki, 2008). In addition,
new evidence has linked the antidepressant effects of the NMDA antagonist ketamine to
BDNF-dependent signaling in the hippocampus (Song et al., 2017), further supporting the
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neurotrophic hypothesis of depression and suggesting a novel mechanism of action for
future antidepressant drugs.
BDNF is also postulated to be involved in the mania that characterizes bipolar
disorder (Tsai, 2004). Lithium, a traditional drug used for the treatment of depression and
bipolar disorder, increases BDNF and Trk-B activation in cerebral cortical neurons
(Hashimoto et al., 2002). Furthermore, there is evidence that a DNA variant in the BDNF
gene confers susceptibility to bipolar disorder (Neves-Pereira et al., 2002), and the
Val66Met polymorphism has been associated with physiological measures in bipolar
disorder, as well as schizophrenia (Bonaccorso et al., 2015). In fact, disrupted BDNF
appears to play a key role in the development of schizophrenia. First, structural and
cognitive changes related to BDNF polymorphisms have been found in patients with
schizophrenia (Agartz et al., 2006; Ahmed, Mantini, Fridberg, & Buckley, 2015). Next, the
time-dependent effects of antipsychotics on BDNF levels in patients with schizophrenia
suggest that the mechanism of their therapeutic action is BDNF-mediated neuroplasticity
(Pandya, Kutiyanawalla, & Pillai, 2013). Finally, animal models of schizophrenia show
altered BDNF expression in the hippocampus of various species (Angelucci, Brene, &
Mathe, 2005), and increased BDNF-mediated hippocampal plasticity has been shown to
protect against related cognitive impairments in rats (Faatehi et al., 2019). Collectively,
these lines of evidence strongly suggest that BDNF is involved in the pathogenesis of
schizophrenia, and that BDNF may be a promising pharmacogenetic target for
schizophrenia and related neuropsychiatric disorders (Han & Deng, 2018; Pillai, 2008).

11

Neurodegenerative disorders
BDNF has also been implicated in the degradation of nerve cells in states of
disease. Several reports have reinforced the idea that altered BDNF activity is a hallmark
feature of neurodegenerative disorders (Murer, Yan, & Raisman-Vozari, 2001). In
Alzheimer’s disease (AD), BDNF mRNA is reduced in the hippocampus of humans
(Phillips et al., 1991). Moreover, rats with amyloid-beta protein injected into the
hippocampus show marked reductions to BDNF activity (Z. Zhang et al., 2005), and
BDNF protein is deregulated in early stages of a transgenic animal model of AD (Iulita et
al., 2017). These findings support the idea that insufficient supply of trophic activity in the
brain corresponds with pathogenic changes to neuronal populations and cellular function
(Murer et al., 2001). Interestingly, BDNF upregulation has been observed in plaguerelated glial cells (Burbach et al., 2004). Since inflammatory and maligned axonal growth
processes have been attributed to amyloid-beta protein activity, areas of the brain
displaying a high degree of BDNF-mediated plasticity, such as the hippocampus, are
particularly vulnerable to plague-associated degeneration (Spires & Hyman, 2004).
BDNF is also involved in the neurodegeneration of the dopaminergic system.
Decreased BDNF mRNA has been reported in the substantia nigra of the midbrain in
people with Parkinson’s disease (Howells et al., 2000), and BDNF/Trk-B expression in
dopaminergic grafts was found reduced in a rat model of Parkinson’s (Sautter et al.,
1998). BDNF may also be used as a treatment in Parkinson’s to ameliorate conditions or
protect against further degeneration. For instance, transfection of BDNF to dopamine
neurons potentiates the effects of a dopamine D3 agonist on striatal innervation,
12

dendritogenesis, and motor behavior (Razgado-Hernandez et al., 2015). In addition,
BDNF receptor blockade has been found to mitigate the neuroprotective effects of
exercise in a rat model of Parkinson’s disease (Real et al., 2013). In Huntington’s disease,
the gene Huntingtin, which normally upregulates BDNF transcription, has a mutation that
leads to BDNF loss (Cattaneo et al., 2001). These deficits in trophic support to striatal
neurons are believed to spell their degeneration and result in the observed pathology
(Zuccato et al., 2001). Investigators believe that pharmacological provisions of BDNF may
conceivably be therapeutic in Huntington’s disease and related degenerative disorders if
applied in the appropriate region- and time-specific manner (Spires et al., 2004; Yulug et
al., 2018).

BDNF and Sleep
Mammalian sleep is a restorative process of the brain and body during which a
number of vital functions take place (Datta, 2010). It is hypothesized that one of these
biological functions of sleep is restoring an organism’s ability to learn and adapt by
facilitating neuroplasticity (Datta, Li, & Auerbach, 2008; Gadea-Ciria, 1976; Walker &
Stickgold, 2006). Sleep can be objectively described as a regulated set of behavioral
states that are defined by physiological traits. Non-rapid eye movement (NREM) sleep is
characterized by synchronized slow wave EEG activity, decreased autonomic activity,
and increased growth-hormone release. Rapid eye movement (REM) sleep is
characterized by desynchronized fast wave EEG activity, dysregulated autonomic
activity, and muscle atonia. The current data suggests that BDNF plays a major role in
several processes during both NREM and REM sleep.
13

BDNF and sleep have been tightly linked. Sleep deprivation significantly alters
BDNF levels (K. Schmitt, Holsboer-Trachsler, & Eckert, 2016; Sei, Saitoh, Yamamoto,
Morita, & Morita, 2000), and, reflectively, human and animal studies have demonstrated
substantial behavioral and cognitive deficits in sleep deprived subjects (Banks & Dinges,
2007; Datta, Mavanji, Ulloor, & Patterson, 2004). Recent studies investigating the link
between sleep and BDNF have suggested an important role for BDNF in the regulation
of sleep states (Bachmann et al., 2012; Hairston et al., 2004; Kushikata, Fang, & Krueger,
1999). In animal experiments, BDNF injection during wakefulness has been shown to
potentiate slow-wave activity (Faraguna, Vyazovskiy, Nelson, Tononi, & Cirelli, 2008),
total time spent in NREM sleep, and total time in REM sleep (Kushikata et al., 1999)
during the subsequent sleep episode. These data strongly support the neurotrophic
hypothesis of sleep regulation, and currently, the field continues to investigate the extent
of BDNF involvement in sleep and search for ancillary mechanisms.
Altered BDNF may play a role in sleep disturbances and sleep-related disorders.
Poor sleep quality is related to alterations in BDNF concentration (Monteiro et al., 2017),
and there is evidence of an interplay between insomnia, stress-induced dysregulation of
the HPA axis, and BDNF deficiency (Jiang & Zhu, 2015; K. Schmitt et al., 2016). A recent
report has associated decreased peripheral BDNF with the cognitive impairments of
insomnia (Fan et al., 2019). Interestingly, this report and related findings correspond with
the loss of slow-wave activity and nighttime awakenings in people with Alzheimer’s
disease (Garcia-Rill, Luster, Mahaffey, Bisagno, & Urbano, 2015; Vitiello & Prinz, 1989).
Finally, poor sleep quality is comorbid with several neurodegenerative disorders (Petit,
14

Gagnon, Fantini, Ferini-Strambi, & Montplaisir, 2004), which have all established a role
for BDNF. Moving forward, investigations in the cellular functions of BDNF can provide
valuable information for understanding the physiology of sleep pathology and for the
diagnosis of related brain disorders.

BDNF and Neuronal Markers of Synaptic Signaling
Neurons are equipped with subcellular mechanisms that govern and maintain
synaptic signaling. Healthy synaptic signaling relies on both synaptic connectivity and
neurotransmitter release. Neuronal markers of pre- and postsynaptic density can help
assess synaptic connectivity, while neuronal markers of transmitter synthesis and
mobilization can indicate levels of neurotransmitter release. Regulation of these synaptic
proteins directly affect synaptic strength, and in general, neuronal communication and
cellular function. Therefore, it is important to understand these markers individually,
collectively, and in various contexts.
The relationship between BDNF and neuronal markers of synaptic signaling has
been an intense area of research. Several reports have indicated that BDNF, through its
dynamic trophic actions, regulates molecular components of synaptic signaling. This has
great implications for the study of healthy neuronal and neurologic functions. Moreover,
interactions between BDNF and synaptic markers have been implicated in pathological
conditions of the central nervous system. The following sections will introduce pre- and
postsynaptic elements of synaptic connectivity and neurotransmission, discuss what
might occur when these elements are disrupted, and describe their known interactions
with BDNF.
15

Synaptophysin
Synaptophysin is the ubiquitous membrane-bound protein of synaptic vesicles
residing in the presynaptic terminal of nerve cells (Wiedenmann & Franke, 1985). It is
believed to participate in presynaptic vesicle docking processes that promote transmitter
release during neurotransmission (Thiel, 1993). The protein’s function has also been
associated with that of the synapsins, a family of vesicle proteins responsible for vesicle
mobilization and exocytosis (Senda, Ochiai, Nakai, & Fujita, 1991). Due to its ubiquity in
presynaptic terminals and its interaction with other vesicle proteins, immunostaining of
synaptophysin has been traditionally used for quantification of synapses (Calhoun et al.,
1996), and as a neuronal marker of presynaptic density (Masliah, Terry, Alford, &
DeTeresa, 1990).
In disease states, presynaptic mechanisms of vesicle mobilization may be
disrupted. For example, research has related reductions of synaptophysin in the striatum
to the degeneration of spinous neurons in Parkinson’s disease (Goto & Hirano, 1990).
Additionally, increased tau phosphorylation has been associated with decreased
synaptophysin levels in a mouse model of Alzheimer’s disease (Garringer et al., 2013).
Disrupted synaptophysin has also been implicated in behavioral and cognitive deficits.
For example, total elimination of synaptophysin in mice incurs substantial behavioral
changes, including impaired object recognition, deficits in spatial learning, and increased
exploratory behavior (U. Schmitt, Tanimoto, Seeliger, Schaeffel, & Leube, 2009). Current
research continues to focus on the role synaptophysin plays in neurodegenerative
disorders, and how deficits in presynaptic density contributes to neurologic impairments.
16

It

has

been

established

that

BDNF

potentiates

the

high

frequency

neurotransmission of LTP, in part, by inducing physiological changes in the presynaptic
terminal (B. Lu & Gottschalk, 2000). Interestingly, BDNF KO mice display impairments to
high frequency neurotransmission along with corresponding reductions to synaptophysin
expression (L. D. Pozzo-Miller et al., 1999). BDNF has also been shown to modulate
presynaptic levels of synaptophysin in the rat hippocampus (B. Lu & Chow, 1999),
suggesting that synaptophysin is likely involved in neurotrophin-induced synaptic
plasticity (Janz et al., 1999). Synaptophysin may also mediate some of BDNF’s
neuroprotective effects. For example, recent research has shown that BDNF transfection
increases synaptophysin expression to promote neural recovery in rats with cerebral
infarction (Y. Zhang et al., 2017). Taken together, the evidence presented here suggests
that synaptophysin is an important mediator of BDNF action, and its functional expression
is linked to the expression of BDNF.
Postsynaptic density 95
The postsynaptic density (PSD) is an assembly of proteins anchored to the
membrane of the postsynaptic nerve cell (Banker, Churchill, & Cotman, 1974). The PSD
region faces the presynaptic active zone and ensures tight coordination between
neurotransmitter release sites and postsynaptic receptors (Tachibana & Sobue, 2000).
Postsynaptic density protein of 95 kDa (PSD-95) is a protein enriched in the PSD,
constituting 2.3% of its total mass. PSD-95 is anchored to the NR2 subunit of N-methylD-aspartate (NMDA) receptors, the major receptors that bind glutamate (Kornau,
Schenker, Kennedy, & Seeburg, 1995). Several reports propose that PSD-95 situates
17

NMDA receptors in the postsynaptic membrane and serves as a multi-domain anchoring
site for several downstream scaffolding and structural proteins (Elias, Elias, Apostolides,
Kriegstein, & Nicoll, 2008; Kennedy, 1997; Yoshii & Constantine-Paton, 2014). As such,
PSD-95 is widely used as a neuronal marker of postsynaptic density at excitatory
synapses (Hunt, Schenker, & Kennedy, 1996; Nagura et al., 2012). When examined
alongside neuronal markers of presynaptic density, its expression reflects synaptic
connectivity and stability (Elibol-Can, Kilic, Yuruker, & Jakubowska-Dogru, 2014; Kim et
al., 2007).
Alterations to postsynaptic density have been implicated in disease states and
associated with behavioral impairments. Downregulated PSD-95 expression in the
prefrontal cortex is believed to underlie the deficits in glutamatergic signaling found in
schizophrenia (Ohnuma et al., 2000), and redistribution of PSD-95 in the striatum has
been reported in animal models of Parkinson’s disease (Nash, Johnston, Collingridge,
Garner, & Brotchie, 2005). In an experimental model of temporal lobe epilepsy, decreased
levels of PSD-95 in the hippocampus were correlated with behavioral deficits in rats,
including measures of anxiety, locomotor activity, spatial learning and memory (Sun et
al., 2009). Additionally, an age-dependent decline in motor neocortex performance in
BDNF knockdown mice correlates with a decrease in cortical PSD-95 expression
(Carreton et al., 2012). These evidences clearly support the idea that disrupted PSD-95
expression relates to pathologic changes to synaptic connectivity and the glutamatergic
system.
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There is also abundant evidence that the PSD plays a crucial role in hippocampal
plasticity.

PSD-95

has

known

involvement

with

α-amino-3-hydroxy-5-methyl-4-

isoxazolepropionic acid (AMPA) receptor accumulation at the synapse. Previous studies
have verified that PSD-95 gene transcription is upregulated by neuronal activity (Beique
et al., 2006), and its recruitment to the PSD facilitates AMPA receptor insertion during
LTP (Meyer, Bonhoeffer, & Scheuss, 2014). Furthermore, the PSD is found to increase
during synaptic plasticity along with a net increase in synaptic size and strength after LTP
is induced (Meyer et al., 2014), which suggests a role for neurotrophins in regulating the
PSD. BDNF has known interactions with the microstructures of the PSD. A previous study
has shown that BDNF is responsible for the transport of PSD-95 to the PSD through PI3KAkt signaling downstream of NMDA receptor activation (Yoshii & Constantine-Paton,
2007). A more recent study reported an increase in PSD-95 expression in the mouse
hippocampus following BDNF treatment (Hu et al., 2011). Together, these evidences
suggest that BDNF regulates the expression of PSD-95.
Vesicular glutamate transporter 2
Glutamate is the major excitatory neurotransmitter found throughout the central
nervous system. In the presynaptic nerve terminal, glutamate is stored in synaptic
vesicles. Vesicular glutamate transporters (VGLUTs) are a family of proteins embedded
in vesicle membranes. Unlike excitatory amino acid transporters (EAATs), VGLUTs are
not involved in removing glutamate from the synaptic cleft. Instead, they perform the role
of vesicle loading inside the presynaptic terminal of excitatory synapses (Vandenberg,
1998). There are three types of VGLUTs known, VGLUT 1-3 (Herzog et al., 2004; Naito
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& Ueda, 1983; Takamori, Rhee, Rosenmund, & Jahn, 2001). These transporters display
nearly identical uptake characteristics and they each affect quantal release of glutamate
(Shigeri, Seal, & Shimamoto, 2004). Immunoreactivity of VGLUT2 has been used to
indicate levels of glutamatergic activity, specifically, pre-synaptic glutamate recycling
(Takamori et al., 2001). More recently, VGLUT2 has been used as a neuronal marker of
presynaptic regulation of glutamate release (Moechars et al., 2006) and spatial-specific
activity at excitatory synapses (Wozny et al., 2018).
Excitotoxicity is a well-established outcome of excess glutamate in the synapse.
Overexpression of VGLUTs leads to dysregulated glutamate release, and has been
shown to cause excitotoxic neurodegeneration (Daniels, Miller, & DiAntonio, 2011).
Increased VGLUT expression is also linked to excitotoxic neuropathological phenotypes,
such as early lethality, behavioral deficits, and neuronal pathology (Daniels et al., 2011),
which have all been observed in human and animal models of schizophrenia (Uezato,
Meador-Woodruff, & McCullumsmith, 2009). Conversely, VGLUT expression is
decreased in mood disorders, including major depressive disorder (MDD) and bipolar
disorder (Uezato et al., 2009). In functional studies, selective global deletion of VGLUT2
in mice has been linked to impaired spatial memory function (Nordenankar et al., 2015)
and increased vulnerability to neurotoxin-induced neurotoxicity (Shen et al., 2018). In the
hippocampus, VGLUT2 irregularities have been associated with cognitive deficits (King
et al., 2014) and age-dependent impairments to learning and memory (Jung et al., 2018).
VGLUT expression is tightly linked to glutamate release and regulation of
excitatory synapses. Since BDNF is known to strengthen excitatory synapses and
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contribute to LTP, BDNF may be involved in regulating VGLUT expression in the
hippocampus. Fluorescence microscopy imaging of cultured hippocampal neurons has
shown that BDNF stimulation during embryonic development upregulates the expression
and distribution of VGLUT isoforms (Melo et al., 2013). In addition, inhibition of Trk-B
prevents BDNF-induced upregulation of VGLUT2 during development (Melo et al., 2013).
However, the relationship between BDNF and VGLUT2 in the adult hippocampus has not
been thoroughly described.
Choline acetyltransferase
Choline acetyltransferase (ChAT) is a transferase enzyme that is responsible for
the synthesis of the transmitter acetylcholine (Ach) (Berman, Wilson, & Nachmansohn,
1953). It is found in high concentrations in cholinergic neurons throughout the central
nervous system (Oda, 1999). Produced in the cell body, ChAT is transported down the
axon to the presynaptic nerve terminal, where it carries out its catalytic functions. ChAT
exists in two forms: a soluble form and a membrane-bound form (Tandon, Bachoo,
Weldon, Polosa, & Collier, 1996). The soluble form is the most productive, accounting for
a large percentage of total enzyme-activity in the cytoplasm (Pahud et al., 1998). The
membrane-bound form is believed to be associated with synaptic vesicles in the
hippocampus (Carroll, 1994). The presence of ChAT in brain tissue indicates the
presence of acetylcholine, and the expression of this protein is considered a marker of
cholinergic activity (Govindasamy et al., 2004).
Cholinergic activity is very important for several neurologic functions. It plays an
essential role in activating the forebrain (B. E. Jones, 2005), sustained attention
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(Himmelheber, Sarter, & Bruno, 2000), states of sleep (Platt & Riedel, 2011) and learning
and memory (Ridley, Bowes, Baker, & Crow, 1984). Pathologic changes to cholinergic
system are thought to underlie many neuropathologic diseases. For instance, irregular
ChAT levels in the neocortex and hippocampus have been linked to memory loss in
Alzheimer’s disease (Francis, Palmer, Snape, & Wilcock, 1999), and loss of ChAT
immunoreactivity has been related to the motor deficits found in amyotrophic lateral
sclerosis (ALS) (Oda, Imai, Nakanishi, Ichikawa, & Deguchi, 1995). Current research is
focused on understanding the extent to which cholinergic activity is involved in brain
pathology, and whether the molecular components of cholinergic systems are good
therapeutic targets. BDNF may be a potential target, as it has known interactions with
cholinergic subsystems. Ex vivo, BDNF was found to promote the survival and
differentiation of rat embryo cholinergic neurons, and this effect was associated with
increased ChAT levels in those neurons (Alderson, Alterman, Barde, & Lindsay, 1990). It
has also been suggested that BDNF activity in hippocampal neurons is regulated by
cholinergic activity, as pilocarpine, a cholinergic receptor agonist, reportedly increased
hippocampal BDNF expression in situ (da Penha Berzaghi et al., 1993). Finally, it was
shown that ethanol exposure caused age-dependent decreases in both ChAT and BDNF
in the mouse hippocampus (Jamal et al., 2018). Taken together, these lines of evidence
indicate a positive correlation between BDNF and ChAT-mediated cholinergic activity.

Sex Differences in BDNF Expression and the Role of Estrogen
It is well-established that there are sex differences in brain physiology and function.
For example, the volume density of mossy fiber synapses in the CA3 area of the
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hippocampus is higher in females than in males, and this sex difference has been posited
to reflect both pre- and postsynaptic elements (Parducz & Garcia-Segura, 1993). At
baseline conditions, it has been reported that males have higher baseline BDNF gene
expression in the dentate gyrus and CA1 regions compared with females (Kight &
McCarthy, 2017). Spatial-specific sex differences in BDNF expression have also been
identified and associated with behavioral phenotypes. In a recent animal study, restraintstressed female mice, but not males, show decreased BDNF expression in the
hippocampus (Yamaura et al., 2013), indicating that BDNF is differentially expressed in
the male and female brain in response to stressors. These findings and similar reports
have led authors to suggest that neurotrophic activity may be regulated by the sexspecific activity patterns of steroid hormones in the brain (Scharfman & Maclusky, 2005).
Investigations into the actions of steroid hormones have advanced our
understanding of estrogen in the central nervous system. The landmark study conducted
by Woolley et al. (1990) demonstrated that 17b-estradiol (E2) modulates spine density in
the hippocampus (Woolley, Gould, Frankfurt, & McEwen, 1990), and since then, several
studies have examined the extent to which estrogen signaling is involved in neurologic
functions. Recently, it was discovered that the brain also produces its own estrogen (Hojo
et al., 2004). Brain-derived estrogen has been implicated in modulating cognition (Luine,
2008), regulating synaptic plasticity (Foy, Baudry, & Thompson, 2004; Y. Lu et al., 2019),
and promoting neuron survival in both the female and male brain (O'Neill, Chen, &
Brinton, 2004). Estrogen has also been shown to be neuroprotective in the injured CNS
(Scott, Zhang, Wang, Vadlamudi, & Brann, 2012). Intriguingly, the effects of estrogen and
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BDNF in the brain appear to overlap considerably, which has inspired many investigations
into their interactions (Scharfman & MacLusky, 2006). Several reports have shown that
estrogen regulates BDNF expression in the rat hippocampus (Solum & Handa, 2002),
suggesting that estrogen-induced synaptic plasticity may, in part, be mediated by
enhanced BDNF. Furthermore, reduced estrogen and BDNF are observed in several
neurodegenerative disorders, including Alzheimer’s disease and Parkinson’s (Sohrabji &
Lewis, 2006). The classical estrogen receptors, first characterized in 1958, are
understood to transduce the actions of estrogens in the adult brain. Both nuclear
receptors, ER-α and ER-β, as well as the extranuclear receptor GPER1, are expressed
in the hippocampus. They are known to interact with the neurotrophic system via both
genomic and non-genomic mechanisms in an estrogen-dependent manner (Luine, 2008;
Yang et al., 2010).
Estrogen receptor alpha
Estrogen receptor alpha (ER-α) is one of two main types of nuclear receptor that
is activated by estrogen (Walter et al., 1985). ER-α is a transcription factor localized
primarily to the nucleus that is composed of distinct domains important for estrogen
binding, DNA binding, and transcription activation (Dahlman-Wright et al., 2006). ER-α
has also been identified at extranuclear sites, including the plasma membrane and
dendritic spines (Weiland, Orikasa, Hayashi, & McEwen, 1997), which may mediate some
of the non-genomic effects of estrogen (Brann & Mahesh, 2008). ER-α is expressed in
the male and female adult brain and distributed throughout the cortex and in the
hippocampus (Osterlund, Gustafsson, Keller, & Hurd, 2000). Intriguingly, expression in
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these regions tends to decline with age (Adams, Furneaux, & White, 2007). In protein
expression studies, immunoreactivity of ER-α has been used to demonstrate spatialspecific ER-α expression (Su et al., 2001) and indicate the neuronal actions of estrogen
in the brain (Lee, Kim, & Choi, 2012).
In the adult brain, ER-α- appears to be primarily involved in regulating reproductive
functions (Lee et al., 2012). However, ER-α may also mediate estrogen’s cognitive
effects. Evidence that ER-α is involved in cognitive function comes from functional
studies, in which ER-α knockout mice display impaired memory performance in
hippocampal-dependent tasks (Fugger, Foster, Gustafsson, & Rissman, 2000). These
cognitive effects may be explained, in part, by the trophic-like effects of ER-α activation.
Previous studies have demonstrated a rapid increase in spine density of hippocampal
CA1 neurons following an ER-α selective agonist, and this effect could be blocked by an
ER-α selective antagonist (McEwen, Tanapat, & Weiland, 1999). This finding
demonstrates a possible nongenomic mechanism by which ER-α mediates estrogeninduced synaptic plasticity, though whether these structural effects are limited to
nongenomic mechanisms remains a topic of inquiry (Brann, Dhandapani, Wakade,
Mahesh, & Khan, 2007).
ER-α expression rapidly changes in response to injury, suggesting that ER-α may
mediate the neuroprotective effects of estrogen in the adult brain. Evidence of ER-αmediated neuroprotection comes from studies of ovariectomized (OVX) rats subjected to
brain injury, in which estrogen-mediated neuroprotection was lost in OVX ER-α-knockout
mice (Dubal et al., 2001; Merchenthaler, Dellovade, & Shughrue, 2003). Additionally, ER25

α agonists have been shown to protect hippocampal neurons against glutamate-induced
excitotoxicity (L. Zhao, Wu, & Brinton, 2004). However, this result has not always been
obtained (Sampei et al., 2000). Currently, work is still underway to determine the extent
of ER-α’s involvement in the neuroprotective effects of estrogen (Lim et al., 2018).
There is accumulating evidence that estrogen regulates BDNF levels in the healthy
and injured CNS (Y. Liu et al., 2001; Solum & Handa, 2002; X. Zhao et al., 2003). An
early study identified an estrogen response element (ERE) sequence within the BDNF
gene (Klinge, 1999), which can bind to an estrogen receptor complex and regulate BDNF
transcription. Moreover, other mechanisms, such as novel estrogen receptor-interacting
proteins (Brann, Zhang, Wang, Mahesh, & Vadlamudi, 2008), NMDAR subunit regulation
(Gazzaley, Weiland, McEwen, & Morrison, 1996), and non-genomic transsynaptic
mechanisms (Blurton-Jones, Kuan, & Tuszynski, 2004) may provide alternative means
by which ER-α regulates BDNF expression. Further work is needed to address this issue.
Estrogen receptor beta
Estrogen receptor beta (ER-β) is the other major type of nuclear receptor that is
activated by estrogen. ER-β is a transcription factor localized primarily to the nucleus that
is composed of an N-terminal DNA binding domain and C-terminal ligand binding domain.
Like ER-α, ER-β is also found at various extranuclear sites, including the plasma
membrane, dendritic shafts, and dendritic spines. In both males and females, ER-β is
expressed throughout various regions of the prefrontal cortex and the hippocampus, with
its expression in the hippocampus being higher than that of its related isoform ER-α
(Osterlund et al., 2000). Upon estrogen-dependent activation of ER-β at the nucleus, the
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encoded protein interacts with DNA sequences to initiate genomic effects. ER-β
immunoreactivity has been used to demonstrate spatial-specific ER-β expression
(Register, Shively, & Lewis, 1998) and indicate the neuronal actions of estrogen in the
brain (Lee et al., 2012).
Like ER-α, ER-β has been implicated in cognition and synaptic plasticity (Li, Cui,
& Shen, 2014). For instance, activation of ER-β has shown to regulate hippocampal
plasticity and improve memory (F. Liu et al., 2008). In functional studies, ER-β knockout
mice display impairments in hippocampal-mediated fear conditioning and retrieved
hippocampal slices show significant deficits in LTP amplitudes (Day, Sung, Logue,
Bowlby, & Arias, 2005). A more recent study reported increased spine density and newly
formed spines in the cortex of female mice after ER-β activation (Wang, Zhu, & Xu, 2018).
These data support a role for ER-β in regulating synaptic plasticity in the hippocampus
and improving hippocampal-dependent cognitive function.
ER-β has been shown to mediate the neuroprotective effects of estrogen. Studies
using selective ER-β agonist have shown to be protective against global ischemia
(Carswell, Macrae, Gallagher, Harrop, & Horsburgh, 2004). ER-β subtype agonists have
also shown to protect against glutamate-induced excitotoxicity (L. Zhao et al., 2004).
Estrogen may exert its neuroprotective effect through its activation of ER-β in astrocytes,
as neuroprotective effects of ER-β expressing astrocytes in the cortex have been
demonstrated in vivo (Dhandapani, Wade, Mahesh, & Brann, 2005). Currently, work is
still underway to determine the extent of ER-β’s involvement in the neuroprotective effects
of estrogen (Lim et al., 2018).
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G protein-coupled estrogen receptor 1
G protein-coupled estrogen receptor 1 (GPER1) is a recently discovered protein
that binds estradiol. It is a seven-pass transmembrane protein primarily localized to the
cytoplasmic face of the endoplasmic reticulum and plasma membrane (Funakoshi, Yanai,
Shinoda, Kawano, & Mizukami, 2006). Like the two ER-receptor subtypes, GPER1 is
reported to be expressed in the cortex and the hippocampus in various species
(Funakoshi et al., 2006). Binding of estradiol to GPER1 results in intracellular calcium
release and synthesis of phosphatidylinositol (3,4,5)- triphosphate (PIP3) in the nucleus
(Revankar, Cimino, Sklar, Arterburn, & Prossnitz, 2005). Hence, activation of this receptor
plays a role in the rapid nongenomic signaling that is observed following estrogen-induced
stimulation (Prossnitz, Arterburn, & Sklar, 2007). In protein expression studies, GPER1
immunoreactivity has been used to demonstrate spatial-specific GPER1 expression
(Brailoiu et al., 2007) and indicate the rapid nongenomic effects of estrogen in the brain
(Tang et al., 2014).
In the basal forebrain, GPER1 co-localizes with cholinergic neurons (Hammond,
Nelson, & Gibbs, 2011) and has been shown to play a role in mediating the effects of Ach
release in the hippocampus (Gibbs, Nelson, & Hammond, 2014). In the hippocampus,
GPER1 appears to promote hippocampal-dependent memory functions, including spatial
memory (Y. Y. Zhang et al., 2019). More directly, GPER1 has been shown to interact with
BDNF in the hippocampus. A recent study has found that both estradiol and GPER1specific agonist rapidly induce BDNF release in field CA3 of the hippocampus, suggesting
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a novel mechanism by which BDNF and estrogen regulate hippocampal synaptic
plasticity (Briz, Liu, Zhu, Bi, & Baudry, 2015).
Like the previously discussed ER subtypes, GPER1 has been implicated in
mediating the neuroprotective effects of estrogen, as well. For instance, the GPER1agonist, G-1, was shown to protect against apoptotic cell death and enhance motor
functional recovery after brain injury (Cheng et al., 2016). Intriguingly, this effect was
shown to be downstream of the PI3K/Akt pathway, previously mentioned as one of three
main intracellular signaling pathways downstream of BDNF/Trk-B. Other studies have
also linked the neuroprotective action of GPER1 to PI3K/Akt signaling, and additionally,
to ERK signaling (Deng et al., 2017), suggesting an overlap in neuroprotective pathways
between BDNF and E2. Clearly, GPER1 holds great promise as a potential target for
therapy. However, more research is required to elucidate the precise mechanisms by
which GPER1 mediates neuroprotection, and further, the extent to which BDNF is
involved.

Significance of the Study
BDNF signal transduction is linked to neuron survival, synaptic stability, and
sustained plastic changes in the hippocampus. Several diseases of the central nervous
system involve dysregulation of the BDNF system, which is known to confer disruptions
to neuronal function. Currently, efforts are underway to fully realize BDNF as a therapeutic
target. However, the basal relationship between BDNF signaling and various components
of neuronal function remains a less explored avenue of research. It stands to reason that,
in order to understand the role of BDNF in disease, it is important to first characterize the
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role of BDNF in healthy, normal function. In addition, sex differences in BDNF signaling
and function have been reported. Intriguingly, the differential actions of BDNF have been
posited to reflect the sex-dependent actions of sex hormones in the brain. Since sexspecific risk factors have become increasingly salient in epidemiology, it becomes
important to characterize BDNF in relation to estrogen signaling in the brain. Therefore,
to contribute to the field, this study aims to determine the effects of chronic BDNF loss on
synaptic signaling in the hippocampus and explore a potential role of estrogen signaling
in modulating this relationship. We hypothesize that synaptic signaling is disrupted in an
animal model of BDNF loss, and that this disruption involves sex-dependent alterations
to estrogen receptor signaling.
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CHAPTER THREE
MATERIALS AND METHODS
Animals
Young adult male (n = 9) and female (n = 9) Sprague Dawley rats were used for
this study. The rats were housed individually in a home cage with free access to food and
water. Half of each males and females were wild type (WT) rats while the other half were
BDNF heterozygous knockout rats (BDNF+/-) (SAGE Labs, Boyertown, PA). The BDNF+/animals had a seven base pair deletion in the BDNF gene. Animals were divided into
groups by sex and strain: WT females (n = 5), WT males (n = 5), BDNF KD females (n =
4), and BDNF KD males (n = 4). All the female rats for the study were used as random
cycling and the estrous cycle was not monitored. All procedures were performed in
accordance with the NIH Guidelines for the Care and Use of Laboratory Animals at the
University of Tennessee.

Tissue Harvest
Animals were euthanized using isoflurane overdose. Animals were decapitated
and the brains were removed. Individual brains were cut at the midsagittal plane and the
hippocampus from each hemisphere was dissected out. Hippocampal tissues were stored
at -20°C and homogenized for protein detection via Western blot analysis.

Tissue Lysis
Hippocampal tissue was homogenized using RIPA buffer (Teknova). Tissue
suspended in RIPA buffer was subjected to sonication (power level: 2) until the tissue
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was visibly solubilized in the buffer. The homogenized tissue was then allowed to rest on
ice for 1 min. The homogenate was centrifuged at 12,000 rpm for 10 minutes. Supernatant
was collected in fresh tubes and used for further protein analyses.

Protein Estimation
The bicinchoninic acid method (BCA Protein Assay Kit, Thermo Fisher Scientific)
was used for quantification of total protein in each sample. Protein estimation was
performed using the 96-well plate method, as per the instructions of the kit. Bovine Serum
Albumin (BSA) was used as the standard. Absorbance was measured at 562 nm using a
Biotek plate reader and the protein concentration was calculated using Gene5 software.

Western Blotting
The samples for western blotting were prepared by mixing 1X Laemmli buffer
(BioRad) with tissue homogenate and incubating in a water bath at 100°C for 10 min.
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was
performed by loading the samples on 4-20% precast gels (BioRad). Protein samples
were then transferred on 0.45 µm nitrocellulose membrane (80V for 90 min) and
blocked using 5% BSA for 1 hour at room temperature on shaker. The blots were then
incubated with primary antibody (Table 3.1) overnight at 4°C on shaker. After the
primary antibody incubation, blots were washed with 1X TBST (10 min X 3) and
incubated with the respective HRP-conjugated secondary antibody. Following this, blots
were washed, developed using ECL (Clarity Western ECL substrate, BioRad), and
scanned using chemiluminescence on Chemidoc Touch Imaging System (BioRad).
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Table 3.1. Primary Antibodies used for Western Blotting
Name
BDNF
Synaptophysin
PSD-95
VGlut2
ChAT
ER-α
ER-β
GPER1
GAPDH
Beta-actin
Vinculin

Company
Thermo Fisher Scientific
Abcam
Abcam
Sigma
Abcam
Abcam
Thermo Fisher Scientific
Lifespan Biosciences
Abcam
R&D Systems
BioRad

Catalog #
OSB00017W
ab8049
ab18258
V2514
ab181023
ab32063
PA1-313
LS-C403194
ab8245
MAB8929
MCA465GA

Quantification of Proteins
Blots were quantified using ImageJ software downloaded from NIH.gov. The band
intensity was measured and corrected for the corresponding housekeeping values. Data
are presented as average fold change of each group. Error bars indicate positive standard
error of the mean.

Statistical Analysis
Multiple t tests were used to compare significance between sex matched groups;
WT males compared to BDNF KD males; WT females compared to BDNF KD females.
Statistical significance was determined using the Bonferroni-Dunn method, with alpha set
to 0.05. Analyses were performed using PRISM software (version 7).

33

CHAPTER FOUR
RESULTS
Western Blot Confirms BDNF Heterozygous Knockout
The animals used in our study had a 7-base pair deletion in the BDNF gene,
resulting in a genetic model of BDNF loss. To verify that our BDNF KD animals had
functional deficits in BDNF protein expression, we first examined both forms of functional
BDNF in the mutant animals. As seen in Figure 4.1, protein levels of pro- and mature
BDNF were detected from hippocampal tissue harvested shortly after euthanasia.
Western blot results are shown in Figure 4.1A-B while quantification of the results from
all samples is shown in Figure 4.1C. The data are represented in terms of normalized
protein expression as compared to Wild Type (WT) animals. As shown in Figure 4.1, the
results demonstrate that protein levels of BDNF are decreased in the hippocampus in
both male and female BDNF KD rats. Statistical analysis, as shown in Table 4.1, revealed
that the reduction of proBDNF in the males was significant (p < .05). While the reduction
in the KD females was not statistically significant, the p value, 0.055, is right at the brink
of significance. For mature BDNF, the statistical analysis (Table 4.2) revealed that there
were significant reductions in both males and females following KD of BDNF.
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Figure 4.1. Western blot analysis confirmed BDNF heterozygosity. Tissue samples were collected from
the hippocampus of adult BDNF KD and WT rats, both males and females. (A, B) Western blot images of
BDNF expression in the female and male hippocampus show visual reductions in BDNF in the mutant (KD)
rats, as compared to WT controls. (C) Quantification of blots indicates reductions in BDNF in both male and
female KD rats. (*, p < 0.05).
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Table 4.1. Statistical Analysis for proBDNF
Gender

Significant?

P-value

Mean of WT

Mean of KD

T ratio

df

Adjusted P value*

Female

No

0.027786

0.9020

0.6025

2.768

7

0.055572

Male

Yes

0.001533

1.034

0.4950

5.019

7

0.003065

Note: * = Adjusted using Bonferroni-Dunn method.

Table 4.2. Statistical Analysis for Mature BDNF.
Gender

Significant?

P-value

Mean of WT

Mean of KD

T ratio

df

Adjusted P value*

Female

Yes

0.013222

0.6880

0.4000

3.294

7

0.026443

Male

Yes

0.003192

1.024

0.4725

4.391

7

0.006384

Note: * = Adjusted using Bonferroni-Dunn method.
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BDNF Knockdown and Altered Synaptic Densities
Synaptophysin
To understand the effects of BDNF loss on synaptic connectivity, we examined the
effects of BDNF KD on synaptophysin expression in the hippocampus of both male and
female rats. As shown in Figure 4.2, protein levels of synaptophysin were detected using
western blot analysis. Representative immunoblots are shown in Figure 4.2A-B.
Quantification of blots is shown in Figure 4.2C. As shown in Figure 4.2, the results
demonstrated that protein levels of synaptophysin are significantly increased in BDNF KD
males. Although BDNF KD females showed decreased levels of synaptophysin relative
to WT females, the difference is not statistically significant (Table 4.3). The increase in
synaptophysin in the BDNF KD males is suggestive of an altered presynaptic component
of synaptic connectivity.
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Figure 4.2. Synaptophysin was increased in BDNF KD males. Tissue samples were collected from the
hippocampus of adult BDNF KD and WT rats, both males and females. (A) Western blot images of
synaptophysin protein expression in female hippocampus samples show a visual decrease in the KD rats,
as compared to WT controls. (B) Western blot images of synaptophysin protein expression in male
hippocampus show a visual increase in the KD rats, as compared to WT controls. (C) Quantification of
immunoblots showed a significant increase in synaptophysin protein in the mutant males, relative to WT
males. The difference between female groups is not statistically significant. (*, p < 0.05).
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Table 4.3. Statistical Analysis for Synaptophysin.
Gender

Significant?

P-value

Mean of WT

Mean of KD

T ratio

df

Adjusted P value*

Female

No

0.169570

2.226

0.8975

1.531

7

0.339140

Male

Yes

0.020749

0.5140

1.728

2.972

7

0.041498

Note: * = Adjusted using Bonferroni-Dunn method.

39

Postsynaptic density 95 (PSD-95)
Synaptic connectivity was further examined using PSD-95 as a neuronal marker
of postsynaptic density. We examined the effects of BDNF KD on PSD-95 expression in
the hippocampus of both male and female rats. As shown in Figure 4.3, protein levels of
PSD-95 were detected using western blot analysis. Representative immunoblots are
shown in Figure 4.3A-B. Quantification of blots is shown in Figure 4.3C. As shown in
Figure 4.3, the results demonstrated that protein levels of PSD-95 were significantly
decreased in BDNF KD males. PSD-95 expression levels did not differ significantly
between the female groups (Table 4.4). The decrease in PSD-95 in BDNF KD males is
suggestive of an altered postsynaptic component of synaptic connectivity.
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Figure 4.3. PSD-95 was decreased in BDNF KD males. Tissue samples were collected from the
hippocampus of adult BDNF KD and WT rats, both males and females. (A) Western blot images of PSD95 protein expression in female hippocampus samples are comparable between groups. (B) Western blot
images of PSD-95 protein expression in male hippocampus show a visual decrease in the KD rats, as
compared to WT controls. (C) Quantification of immunoblots showed a significant decrease in PSD-95
protein in the mutant males. (*, p < 0.05).
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Table 4.4. Statistical Analysis for PSD-95.
Gender

Significant?

P-value

Mean of WT

Mean of KD

T ratio

df

Adjusted P value*

Female

No

0.515249

0.7980

0.9650

0.685

7

>0.99999

Male

Yes

0.006444

1.064

0.3333

4.088

7

0.012887

Note: * = Adjusted using Bonferroni-Dunn method.
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Vesicular glutamate transporter 2 (VGLUT2)
VGLUT2 is a neuronal marker of presynaptic glutamatergic activity. It is widely
used as a marker for glutamatergic neurons. We examined the effects of BDNF KD on
VGLUT2 expression in the hippocampus of both male and female rats. As shown in Figure
4.4, protein levels of VGLUT2 were detected using western blot analysis. Representative
immunoblots are shown in Figure 4.4A-B. Quantification of blots is shown in Figure 4.4C.
As shown in Figure 4.4, the results demonstrated that protein levels of VGLUT2 were
comparable to those of WT controls, in both males and females. No statistically significant
changes were observed (Table 4.5), suggesting that VGLUT2 expression is unaltered in
BDNF KD animals relative to WT controls.
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Figure 4.4. VGLUT2 did not differ across sex-matched groups. Tissue samples were collected from the
hippocampus of adult BDNF KD and WT rats, both males and females. (A) Western blot images of VGLUT2
protein expression in female hippocampus samples show a visual increase in the KD rats, as compared to
the WT controls. (B) Western blot images of VGLUT2 protein expression in male hippocampus are visually
comparable between groups. (C) Quantification of blots did not indicate any significant differences between
sex-matched groups. (*, p < 0.05).
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Table 4.5. Statistical Analysis for VGLUT2.
Gender

Significant?

P-value

Mean of WT

Mean of KD

T ratio

df

Adjusted P value*

Female

No

0.093050

0.4680

0.7350

1.944

7

0.186101

Male

No

0.854349

0.7520

0.7225

0.191

7

>0.99999

Note: * = Adjusted using Bonferroni-Dunn method.
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Choline acetyltransferase (ChAT)
ChAT is a neuronal marker of presynaptic cholinergic activity as well as an
accepted marker of cholinergic neurons. We examined the effects of BDNF KD on ChAT
expression in the hippocampus of both male and female rats. As shown in Figure 4.5,
protein levels of ChAT were detected using western blot analysis. Representative
immunoblots are shown in Figure 4.5A-B. Quantification of blots is shown in Figure 4.5C.
As shown in Figure 4.5, the results demonstrated that protein levels of ChAT were
comparable to those of WT controls, in both males and females. There was a minor
elevation in protein expression in the BDNF KD animals, however, this change was not
statistically significant (Table 4.6). These results indicate that ChAT expression is
unaltered in BDNF KD animals relative to WT controls.
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Figure 4.5. ChAT did not differ across sex-matched groups. Tissue samples were collected from the
hippocampus of adult BDNF KD and WT rats, both males and females. (A) Western blot images of ChAT
protein expression in female hippocampus samples show a visual increase in the KD males, as compared
to the WT controls. (B) Western blot images of ChAT protein expression in male hippocampus are
comparable between groups. (C) Quantification of blots did not indicate any significant differences between
sex-matched groups. (*, p < 0.05).
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Table 4.6. Statistical Analysis for ChAT.
Gender

Significant?

P-value

Mean of WT

Mean of KD

T ratio

df

Adjusted P value*

Female

No

0.524007

0.4520

0.6350

0.671

7

>0.99999

Male

No

0.389807

0.6140

0.8300

0.917

7

0.779614

Note: * = Adjusted using Bonferroni-Dunn method.
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BDNF Knockdown and Altered Estrogen Receptor Expression
Estrogen receptor alpha (ER-α)
Analysis of ER-α was used to aid to the analysis of underlying mechanisms of sexspecific differences in BDNF action. We examined the effects of BDNF KD on ER-α
expression in the hippocampus of both male and female rats. As shown in Figure 4.6,
protein levels of ER-α were detected using western blot analysis. Representative
immunoblots are shown in Figure 4.6A-B. Quantification of blots is shown in Figure 4.6C.
The protein expression of ER- β was visually lower in WT males relative to WT females
(Figure 4.6A-B). As shown in Figure 4.6, the results are indicative of a trend in which
female mutant rats displayed a minor decrease in ER-α, while male mutants show an
increase in ER-α, relative to their respective WT controls. Statistical analysis, shown in
Table 4.7, revealed that the changes in both males and females were not significant.
These results convey that ER-α mediated estrogen signaling is unaltered in BDNF KD
animals. However, the p value for males, 0.060, was right at the brink of significance.
Appropriate power analysis and increasing the n number for future studies should yield
more stringent statistical evidence and show sex-dependent changes in ER-α expression
following chronic BDNF loss.
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Figure 4.6. ER-α did not differ across sex-matched groups. Tissue samples were collected from the
hippocampus of adult BDNF KD and WT rats, both males and females. (A) Western blot images of ER-α
protein expression in female hippocampus samples show a visual decrease in the KD rats, as compared
to WT controls. (B) Western blot images of ER-α protein expression in male hippocampus show a visual
increase in the KD rats, as compared to WT controls. (C) Quantification of immunoblots did not indicate
significant differences between sex-matched groups. (*, p < 0.05).
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Table 4.7. Statistical Analysis for ER-α.
Gender

Significant?

P-value

Mean of WT

Mean of KD

T ratio

df

Adjusted P value*

Female

No

0.030178

2.112

0.8475

2.710

7

0.060356

Male

No

0.113734

0.7460

1.123

1.807

7

0.227467

Note: * = Adjusted using Bonferroni-Dunn method.
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Estrogen receptor beta (ER-β)
Besides ER- α, ER-β is another important mediator of genomic estrogen signaling
in the brain. We examined the effects of BDNF KD on ER-β expression in the
hippocampus of both male and female rats. As shown in Figure 4.7, protein levels of ERβ were detected using western blot analysis. Representative immunoblots are shown in
Figure 4.7A-B. Quantification of blots is shown in Figure 4.7C. The protein expression of
ER- β was visually lower in WT males as compared to WT females (Figure 4.7A-B). As
shown in Figure 4.7, the results are indicative of a trend in which female mutant rats
displayed a minor decrease in ER-β, while male mutants show an increase in ER-β,
relative to their respective WT controls. Statistical analysis, shown in Table 4.8, revealed
that protein levels of ER-β are significantly increased in male BDNF KD animals as
compared to WT males. There was no statistically significant difference in ER-β between
the female groups (Table 4.8). These results are suggestive of a sex-dependent alteration
in ER-β mediated estrogen signaling after BDNF loss.
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Figure 4.7. ER-β was increased in BDNF KD males. Tissue samples were collected from the
hippocampus of adult BDNF KD and WT rats, both males and females. (A) Western blot images of ER-β
protein expression in female hippocampus samples show a visual decrease in the KD rats, as compared
to WT controls. (B) Western blot images of ER-β protein expression in male hippocampus show a visual
increase in the KD rats, as compared to WT controls. (C) Quantification of immunoblots showed a significant
increase in ER-β protein in the mutant males. The difference between female groups is not statistically
significant. (*, p < 0.05).
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Table 4.8. Statistical Analysis for ER-β.
Gender

Significant?

P-value

Mean of WT

Mean of KD

T ratio

df

Adjusted P value*

Female

No

0.379082

0.9780

0.7500

0.939

7

0.758164

Male

Yes

0.002148

0.1940

0.6075

4.724

7

0.004296

Note: * = Adjusted using Bonferroni-Dunn method.
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G protein-coupled estrogen receptor 1 (GPER1)
A third, most recently discovered estrogen receptor is the GPER1, which primarily
moderates non-genomic estrogen signaling in the brain. GPER1 was used to complete a
thorough analyses of ERs after BDNF loss. We examined the effects of BDNF KD on
GPER1 expression in the hippocampus of both male and female rats. As shown in Figure
4.8, protein levels of GPER1 were detected using western blot analysis. Representative
immunoblots are shown in Figure 4.8A-B. Quantification of blots is shown in Figure 4.8C.
The protein expression of GPER1 was visually lower in WT males as compared to WT
females (Figure 4.8A-B). As shown in Figure 4.8, the results are indicative of a trend in
which female mutant rats displayed a minor decrease in GPER1, while male mutants
show an increase in GPER1, relative to their respective WT controls. Statistical analysis,
shown in Table 4.9, revealed that the changes in both males and females were not
significant. These results convey that GPER1 mediated estrogen signaling is unaltered in
BDNF KD animals. However, the p value for males, 0.076, was close to being significant.
Appropriate power analysis and increasing the n number for future studies should yield
more stringent statistical evidence for sex-dependent changes in GPER1 expression
following chronic BDNF loss.
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Figure 4.8. GPER1 did not differ across sex-matched groups. Tissue samples were collected from the
hippocampus of adult BDNF KD and WT rats, both males and females. (A) Western blot images of GPER1
protein expression in female hippocampus samples show a visual decrease in the KD rats, as compared
to WT controls. (B) Western blot images of GPER1 protein expression in male hippocampus show a visual
increase in the KD rats, as compared to WT controls. (C) Quantification of immunoblots did not indicate
significant differences between sex-matched groups. (*, p < 0.05).
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Table 4.9. Statistical Analysis for GPER1.
Gender

Significant?

P-value

Mean of WT

Mean of KD

T ratio

df

Adjusted P value*

Female

No

0.159127

1.024

0.6975

1.576

7

0.318253

Male

No

0.037972

0.268

0.6050

2.552

7

0.075944

Note: * = Adjusted using Bonferroni-Dunn method.
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CHAPTER FIVE
DISCUSSION AND CONCLUSIONS
Discussion
As discussed earlier, we hypothesized that synaptic signaling is disrupted in a
condition of BDNF loss, and that this disruption involves alterations to estrogen receptor
signaling in a sex-specific manner. We tested this hypothesis using a BDNF+/- KD rodent
model. In agreement with our hypothesis, findings from our study reveal that: (1) BDNF+/KD led to sex-specific alterations in levels of protein expression of synaptophysin and
PSD-95, (2) BDNF loss did not alter protein levels of VGLUT2 or ChAT in either male or
female hippocampus, and (3) sex-specific changes in the hippocampus were observed in
protein expression of ER-β following BDNF+/- KD.
From our initial findings, we observed that there are specific pre- and postsynaptic
molecular changes in the male hippocampus, but not in the female, after BDNF+/- KD.
Presynaptic marker, synaptophysin (Figure 4.2), was significantly increased in the male
KD as compared to WT. But, the postsynaptic marker, PSD95 (Figure 4.3), was
decreased in the KD male as compared to WT. These results are suggestive of a
disrupted neuronal communication/connectivity in the hippocampus, which may be the
underlying cause of several other reported behavioral deficits in relation to BDNF loss
(Linnarsson, Bjorklund, & Ernfors, 1997; Mizuno, Yamada, Olariu, Nawa, & Nabeshima,
2000). No changes in any of the pre- or postsynaptic markers were reported in the female
hippocampus, suggesting a pre-existing rescue mechanism. Other studies have also
confirmed that disrupted BDNF signaling has altered mechanisms of synaptic connectivity
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both in vivo and in vitro (L. D. Pozzo-Miller et al., 1999) (Yoshii & Constantine-Paton,
2014).
Examination of changes in synaptic markers was followed by analyses of neuronaltype specific markers; VGLUT2 and ChAT. These are markers of glutamatergic and
cholinergic neuronal activity, respectively. Recently, others have documented that
disruptions in BDNF signaling lead to deficits in VGLUT2 levels in cultured hippocampal
neurons (Melo et al., 2013), and that BDNF loss corresponds to reductions in ChAT levels
in the mouse hippocampus (Jamal et al., 2018). Our analyses showed that there were no
significant changes in the protein levels of either VGLUT2 or ChAT in both BDNF+/- KD
males as well as females as compared to WT (Figures 4.4 & 4.5). These results tempt us
to reason that BDNF loss may affect neuronal communication but not glutamatergic or
cholinergic neuronal activity. There can be several other underlying mechanisms that may
show a similar effect, and therefore, require further deciphering. Here, we propose a few
possibilities as to why no change in VGLUT2 and ChAT was observed in our model of
chronic BDNF loss. One of the reasons could be that effects of BDNF loss may be
restricted to specific neuronal pathways other than VGLUT2 or ChAT. It is also possible
that there are compensatory mechanisms in the brain to rescue VGLUT2 and ChAT. Time
may also be a factor in our results. For example, BDNF loss and the resulting disruption
of VGLUT2 and ChAT could be occurring in aged animals only. Finally, ChAT and
VGLUT2 expression in BDNF+/- KD animals may be differentially altered by neuronal
insult. Therefore, a next step would be to examine these markers under pathologic
conditions, in relation to BDNF+/- KD.
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Next, the sex-specific significant differences in pre- and postsynaptic markers were
investigated in the context of steroid hormone-specific signaling pathways. For this study,
we looked at the differences in estrogen signaling molecules, the estrogen receptors
(ERs), namely, ER-alpha, ER-beta, and GPER1. Protein expression of all three receptors
showed an expected pattern where WT males had lower levels of ERs as compared to
WT females. Analysis of female groups showed no change in ER expression in KD
females relative WT females (Figures 4.6, 4.7, 4.8). However, our findings reported that
BDNF+/- KD males show a significant increase in ER-β, along with a similar upward trend
in ER-α and GPER1, when compared to respective protein levels in WT males.
Importantly, the increases were not as high as the basal levels in WT females. Given
these results, we believe that BDNF+/- KD in the males led to an activation of the
neuroprotective pathways that may be necessary to rescue the effects of BDNF loss. We
posit that estrogen receptor signaling may achieve these neuroprotective effects. In
support of our interpretation, previous studies have shown that BDNF and estrogen both
serve neuroprotective roles in the male and female brain (Cho et al., 2003; Pandya et al.,
2013), and that estrogen neuroprotection can be mediated by estrogen receptor signaling
(Carswell et al., 2004; Merchenthaler et al., 2003). We propose that, since males have
indigenously low levels of ERs (as shown in Figures 4.6, 4.7, 4.8), they require an
upregulation in ER expression to combat the negative effects of BDNF loss. Further
support of this view comes from the fact that males express higher levels of BDNF mRNA
in the developing hippocampus as compared to females (Kight & McCarthy, 2017),
suggesting a superior functional role of and dependency on BDNF in this region of the
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adult male brain. Hence, BDNF loss in males could be more detrimental to signaling
processes, thereby requiring an alternative neuroprotective response in the form of
estrogen signaling. We believe that the naturally higher levels of ERs in females may
suffice for protective levels of ERs, and, thus, do not require an upregulation of estrogen
receptors after BDNF loss.
Taken together, our study adds a piece in the puzzle of understanding BDNF
action in the brain, more specifically, in the region important for memory and cognition –
the hippocampus. We have examined the effects of BDNF loss under basal conditions,
without any brain insult or other interfering variables. We showed specific neuronal
signaling pathways and estrogen receptor signaling pathways that may play a crucial role
in BDNF action. We also accounted for sex differences, as understanding sexual
dimorphism in the brain is pivotal for the understanding of human physiology. Additionally,
this study adds to the development of therapeutic targets, as BDNF is neuroprotective in
several neuropathologic disorders. Finally, our findings can be implicated in mechanisms
of aging and in post-menopausal health, where reductions in both BDNF and E2 signaling
have been very well documented.
Limitations of the Study
We acknowledge that there are additional investigations that need to be performed
as part of future directions for this project. An important future objective that must be met
is to investigate the temporal and spatial effects of BDNF loss in the brain. To that end,
parallel studies in the lab are investigating the effects of BDNF loss in other limbic
structures, cortex, and the brainstem. As the facts have it, the brain is formed of 90% glial
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cells and 10% neurons. Therefore, it is also imperative to study the effects of BDNF loss
on other cells types and on neuroinflammation. Other studies from our lab have reported
effects of BDNF loss on inflammation in the brain.
Since our results are suggestive of a pattern that involves sex-dependent changes
in estrogen receptor expression, it is important to take into consideration known sexual
dimorphic components of neurophysiology and of the periphery, as well. For example, the
observed changes in our study may be explained, in part, by the sexual dimorphic actions
of select neurosteroid receptors in the brain, including, but not limited to, progesterone,
androgen, and insulin growth factor 1 (IGF1) receptors. While beyond the scope of this
study, future objectives would do well to include such parameters. Furthermore, estrous
activity is known to modulate estrogen receptor expression. Though our female
specimens were on random cycles, controlling for estrous cycle may prove valuable in
determining the causal factors involved in estrogen receptor changes following BDNF
loss.

Conclusions
Our study features an important pre-clinical model with immense translational
value. We conclude that BDNF remains a crucial neurotrophic factor in neuronal signaling
and healthy brain function. Moreover, the effects of BDNF in the brain are different in
males and females and the steroid hormone, estrogen, might be an important mediator
of BDNF action.
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